Polyrizon

Polyrizon CROIC

The Cash Return on Invested Capital (CROIC) of Polyrizon (PLRZ) as of Oct 21, 2026 is -21.60 %. In the previous year, Cash Return on Invested Capital (CROIC) was -21.70 % — a change of -0.45% (higher).

CROIC

-21.60 %

YoY

-0.45%

Last updated:

Cash Return on Invested Capital (CROIC) of Polyrizon is 2025 -21.60 % . Cash Return on Invested Capital (CROIC) of Polyrizon was 2024 -21.70 % . It decreases by -0.45% higher compared to the previous year.

The Polyrizon CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2020
-493.75 USD
Jan 1, 2021
17,033.30 USD
Jan 1, 2022
3,783.33 USD
Jan 1, 2023
-208.95 USD
Jan 1, 2024
-21.70 USD
Jan 1, 2025
-21.60 USD
The Polyrizon CROIC history
YEARCROICYoY
-21.60 %-0.45%
-21.70 %-89.62%
-208.95 %-105.52%
3,783.33 %-77.79%
17,033.30 %-3,549.78%
-493.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon Stock analysis

What does Polyrizon do? Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements. Polyrizon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polyrizon stock

Cash Return on Invested Capital (CROIC) of Polyrizon is -21.60 % in 2025.

Cash Return on Invested Capital (CROIC) of Polyrizon changed from -21.70 % to -21.60 %, representing a -0.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Polyrizon since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Polyrizon with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Polyrizon

All Key Metrics — Polyrizon